Jag Capital Management LLC Continues to Hold Position in Eli Lilly and Company (LLY)

Jag Capital Management LLC held its stake in Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,575 shares of the company’s stock at the end of the second quarter. Jag Capital Management LLC’s holdings in Eli Lilly and were worth $212,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of LLY. First Command Financial Services Inc. boosted its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co acquired a new stake in Eli Lilly and during the first quarter valued at $135,000. Point72 Asia Hong Kong Ltd boosted its stake in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Penserra Capital Management LLC boosted its stake in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Finally, American National Bank boosted its stake in Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares in the last quarter. 75.59% of the stock is owned by institutional investors.

Shares of Eli Lilly and Company (LLY) traded down 0.66% on Friday, hitting $77.29. The company’s stock had a trading volume of 2,379,605 shares. The stock’s 50-day moving average price is $82.55 and its 200-day moving average price is $81.88. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The firm has a market cap of $81.54 billion, a price-to-earnings ratio of 33.44 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.86 EPS. Equities analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.67%. Eli Lilly and’s payout ratio is 90.04%.

ILLEGAL ACTIVITY NOTICE: “Jag Capital Management LLC Continues to Hold Position in Eli Lilly and Company (LLY)” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://sportsperspectives.com/2017/08/18/jag-capital-management-llc-continues-to-hold-position-in-eli-lilly-and-company-lly.html.

Several equities research analysts have recently weighed in on the company. BMO Capital Markets reissued a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. TheStreet raised Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Leerink Swann cut Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $93.00 to $90.00 in a research report on Wednesday, July 26th. Finally, BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company’s stock. Eli Lilly and has a consensus rating of “Hold” and a consensus target price of $88.27.

In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 669,733 shares of company stock valued at $55,845,287. Corporate insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply